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at the end of each chapter, plus full-color
photographs and illustrations, facilitate un-
derstanding of the complex diseases being
discussed.The authors also include a chapter
on laboratory tests used in the diagnosis of
immunological disorders, thereby allowing
the reader to appreciate the importance of
laboratory medicine in clinical outcomes.
The authors execute their case studies well
in the larger context of disease occurrence
in the general population, providing a com-
plete overview of the disease process from
manifestation diagnosis through treatment.
This book is a great study aid and reference
guide for all immunologists. It would make
an ideal text for anyone interested in under-
standing immunological disease from both
diagnosis and treatment standpoints.
UzmaAlam, PhD
Yale University School of Medicine
Department of Epidemiology
and Public Health
Making Cancer History: Disease and
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US $35.00 Hardcover. ISBN: 978-
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In 1981, history professor James Olson
was diagnosed with epitheliod sarcoma and
in 2000, with brain cancer. As a cancer pa-
tient, he endured radiation therapy,
chemotherapy, brain surgery, and amputa-
tion of his left forearm. He uses his own or-
deal as an illustrative example in Making
Cancer History, a meticulous history of the
institution where he was treated: the Univer-
sity ofTexas M.D.Anderson Cancer Center.
Olson combines biographies of prominent
M.D.Anderson personalities with the global
histories of cancer research and treatment to
show how advancements in basic science
and patient care have reduced suffering and
extended lives. Although he renounces any
claim to being dispassionate about the insti-
tution that saved his life, Olson tells the
story as a historian, not omitting the failures
and controversies that must accompany any
mission as ambitious as curing cancer.
Since its establishment in 1941, the
M.D.Anderson Cancer Center has followed
the philosophy of “treat to cure,” which is
echoedintheircurrentmission:“toeliminate
cancer in Texas, the nation, and the world.”
One of its first presidents, R. Lee Clark,
made plans to repurpose the center should a
cure for cancer be found within the decade.
Such optimism seems incredible, but the
progress Olson documents is a testament to
the vision of the early pioneers. At the time
of the center’s founding, the standard cancer
treatment was radical surgery, which re-
moved the tumor, surrounding tissue and
lymphnodes,andofteninvolvedamputation.
In the years that followed, M.D. Anderson
sought to replace radical surgery with mini-
mally invasive treatments such as
chemotherapy and radiotherapy and became
a world leader in cancer prevention and in-
vestigation of environmental cancer causes.
Through its almost 70-year history,
M.D. Anderson has been headed by only
four individuals, and Olson's book is largely
organized around the administrative eras
represented by these four men. From this
emphasis on leadership emerges one of the
book’s central themes: Discovery does not
happen in isolation, it is a product of institu-
tional culture which is itself the product of
inspired leaders.The administration quickly
recognized that treatment of such a complex
disease requires two-way interaction be-
tween scientists trying to understand the dis-
ease and clinicians who have to face the
human side of cancer. The institutional
structure has been continuously adjusted to
maintain a collaborative, multidisciplinary
environment. Even Olson's occasional diver-
sions into dry details such as hospital fi-
nance andTexas university politics illustrate
the multiple levels on which events and in-
dividuals shape an institution.
Although Making Cancer History ap-
pears to present a limited scope ― the his-
tory of a single hospital and its people ―
Olson’s “biography” shows M.D.Anderson
both as a microcosm for the worldwide
progress against cancer and a model for thedevelopment of a successful medical insti-
tution. His story puts the individual struggle
against cancer into a larger context, celebrat-
ing the courage of survivors, medical pro-
fessionals, and scientists throughout history.
Callen Hyland
Department of Molecular, Cellular,
and Developmental Biology
Yale University
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Suso Platero. Hoboken, NJ: Wiley Inc.;
2009. 349 pp. US $115 Hardcover.
ISBN: 978-0470145593.
As the development of drugs continues
to advance in the new decade, the develop-
ment of molecular biomarkers must likewise
advance in order to ensure that patients con-
tinue to receive the best possible standard of
care. In Molecular Pathology in Drug Dis-
covery and Development, editor J. Suso
Platero argues that future medical care will
need to be tailored to individual patients. In
ordertofacilitatethispersonalizedmedicine,
Platero states that clinicians and researchers
ought to work together to produce biomark-
ers and therapeutic agents simultaneously,
thereby streamlining our ability to under-
standdiseasepathology,finddrugtargets,se-
lectpatientslikelytobenefitfromadrug,and
determine the efficacy of new drugs.
Themajorityofthebookfocusesonhow
molecular biomarkers have been utilized in
cancertreatment,althoughtheauthorsdooc-
casionally touch on other diseases such as
HIV/AIDS and cystic fibrosis.Arguably, the
work might be improved by a more in-depth
discussion of the latter diseases, since the
overwhelmingfocusoncancerleadstoacer-
tain level of redundancy between the chap-
ters. On the other hand, it must be
acknowledged that the authors’ depiction of
the historical development of cancer bio-
markersiswelldone.Oneofthecentralideas
put forth over the course of the book is that
clinicians and researchers should always be
open to the development of new biomarkers,
rather than preselecting a set of biomarkers
for a given drug. The authors discuss how
clinical trials may be conducted in order to
discover and incorporate novel biomarkers,
therebyimprovingourunderstandingofboth
disease pathology and treatment feasibility.
MolecularPathologyinDrugDiscovery
and Development also contains a plethora of
technical information on how biomarkers
should be measured and interpreted.The au-
thors discuss thebestways to generatetissue
slides and harvest nucleic acids for analysis.
Various pathological techniques are dis-
cussed, with special emphasis placed on im-
munohistochemistry (IHC), transcriptional
profiling,andautomotivequantitativeanaly-
sis (AQUA). Detailed explanations of how
biomarkers should be analyzed also are pro-
vided, and colored inserts offer readersvalu-
able examplesof how histologicalslides and
microarray results may appear.
What may be the main criticism of the
book is that the authors prefer to discuss in-
stances in which biomarkers already have
been proven to be useful rather than hypoth-
esizing on how biomarkers may evolve in
the future. Although the authors do give a
brief overview of how AQUA may provide
better measurement of biomarkers than IHC,
the majority of the information discussed is
of a technical nature. It seems as though the
work might have benefitted from either an
extended discussion of recently developed
assays or an analysis of how our current use
of biomarkers might be improved. Such a
discussion would give readers an idea of
how they could to contribute to the field.
Overall, Molecular Pathology in Drug
Discovery and Development is a well-writ-
ten book that provides both an overview of
how biomarkers may be developed and de-
tailed explanations of how to measure and
analyze said biomarkers. Although the na-
ture of the book’s subject matter may make
it more useful to clinicians and scientists in-
terested in treating cancer, its in-depth ex-
planations of various assays make it useful
to anyone interested in molecular pathology.
Kathryn Tworkoski
Yale University Graduate School
ofArts and Sciences
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